TAK insider transactions

SEC Form 3 filed by new insider Smoter Jennifer Marie

President and CEO Weber Christophe Pierre was granted 78,900 units of Ordinary Shares and was granted 165,370 units of American Depositary Shares, decreasing direct ownership by 55% to 418,803 units (SEC Form 4) to cover taxes

President, R&D Plump Andrew Stewart was granted 212,470 units of American Depositary Shares, increasing direct ownership by 36% to 806,572 units (SEC Form 4)

Head, Strat. & Port. Dev. Pignagnoli Agosti Marcello was granted 27,740 units of American Depositary Shares, increasing direct ownership by 19% to 172,348 units (SEC Form 4)

Chief Transformation Officer Duprey Lauren Rusckowski was granted 59,990 units of American Depositary Shares, increasing direct ownership by 36% to 228,503 units (SEC Form 4)

CEO - Elect Kim Julie So-Young was granted 105,416 units of American Depositary Shares, increasing direct ownership by 32% to 430,145 units (SEC Form 4)

Chief Data & Tech. Officer Ricci Gabriele was granted 34,994 units of American Depositary Shares, increasing direct ownership by 28% to 159,126 units (SEC Form 4)

Chief Financial Officer Furuta Milano was granted 7,800 units of Ordinary Shares, increasing direct ownership by 16% to 57,900 units (SEC Form 4) (withholding obligation)

President, OBU Bitetti Teresa Marie was granted 64,988 units of American Depositary Shares, increasing direct ownership by 34% to 258,136 units (SEC Form 4)

President, IBU Platford Giles Richard was granted 72,124 units of American Depositary Shares, increasing direct ownership by 32% to 297,363 units (SEC Form 4)

SEC Form 3 filed by new insider Greenway Nicola Deidre Petal

SEC Form 3 filed by new insider Farajallah Awny Samaan Botros

SEC Form 3 filed by new insider Ibrahim Ramy Riad Ahmed

SEC Form 3 filed by new insider Butel Jean Luc

SEC Form 3 filed by Takeda Pharmaceutical Company Limited

SEC Form 3 filed by Takeda Pharmaceutical Company Limited

SEC Form 3 filed by Takeda Pharmaceutical Company Limited

SEC Form 3 filed by Takeda Pharmaceutical Company Limited

SEC Form 3 filed by Takeda Pharmaceutical Company Limited

SEC Form 3 filed by Takeda Pharmaceutical Company Limited

SEC Form 3 filed by new insider Fujimori Yoshiaki

SEC Form 3 filed by Takeda Pharmaceutical Company Limited

SEC Form 3 filed by Takeda Pharmaceutical Company Limited

SEC Form 3 filed by Takeda Pharmaceutical Company Limited

SEC Form 3 filed by Takeda Pharmaceutical Company Limited

SEC Form 3 filed by Takeda Pharmaceutical Company Limited

SEC Form 3 filed by new insider Furney Natalie Anne Marie

SEC Form 3 filed by new insider Kim Julie So-Young

SEC Form 3 filed by new insider Miyabashira Asuka

SEC Form 3 filed by new insider Duprey Lauren Rusckowski

SEC Form 3 filed by Takeda Pharmaceutical Company Limited

SEC Form 3 filed by new insider Reed Kimberly A.

SEC Form 3 filed by Takeda Pharmaceutical Company Limited

SEC Form 3 filed by Takeda Pharmaceutical Company Limited

SEC Form 3 filed by Takeda Pharmaceutical Company Limited

SEC Form 3 filed by Takeda Pharmaceutical Company Limited

SEC Form 3 filed by Takeda Pharmaceutical Company Limited

Large owner Takeda Pharmaceutical Co Ltd converted options into 1,250,000 shares (SEC Form 4)

SEC Form 3: New insider Takeda Pharmaceutical Co Ltd claimed ownership of 840,500 shares (Amendment)

SEC Form 3: New insider Takeda Pharmaceutical Co Ltd claimed ownership of 500,000 shares

SEC Form 3 filed by new insider Takeda Pharmaceutical Co Ltd

SEC Form 4: Takeda Pharmaceutical Co Ltd converted options into 1,615,427 shares

SEC Form 3 filed by new insider Takeda Pharmaceutical Co Ltd

SEC Form 3 filed by Takeda Pharmaceutical Company Limited